Blau syndrome, clinical and genetic aspects

Autoimmunity Reviews

Volumn 12, Issue 1, 2012, Pages 44-51

  Sfriso, Paolo ^a   Caso, Francesco ^a   Tognon, Sofia ^a   Galozzi, Paola ^a   Gava, Alessandra ^a   Punzi, Leonardo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Autoinflammatory disease; Blau syndrome; Camptodactyly; Genetic mutation; NOD2; Uveitis

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; HLA A24 ANTIGEN; HLA B18 ANTIGEN; HLA B51 ANTIGEN; HLA DQ ANTIGEN; HLA DR11 ANTIGEN; INFLIXIMAB; INTERLEUKIN 1BETA; METHYLPREDNISOLONE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; STEROID; THALIDOMIDE;

ADAPTIVE IMMUNITY; ARTHRITIS; AUTOPHAGY; BLAU SYNDROME; BRAIN INFARCTION; CHORIORETINITIS; DISEASE SEVERITY; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; ETHNIC GROUP; FEVER; FOLLOW UP; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HLA TYPING; HUMAN; HYPERGAMMAGLOBULINEMIA; INTERSTITIAL PNEUMONIA; IRIDOCYCLITIS; LOW DRUG DOSE; LYMPHADENITIS; MAINTENANCE DRUG DOSE; MORBIDITY; MULTIPLE CYCLE TREATMENT; OLIGOMERIZATION; ONSET AGE; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; RETINA DETACHMENT; REVIEW; SEQUENCE ALIGNMENT; SKIN MANIFESTATION; SUBCUTANEOUS NODULE; TRANSCRIPTION INITIATION; UPREGULATION;

CRANIAL NERVE DISEASES; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; NOD2 SIGNALING ADAPTOR PROTEIN; SYNOVITIS; UVEITIS;

EID: 84866874147     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.07.028     Document Type: Review

References (77)

1. Punzi L., Gava A., Galozzi P., Sfriso P. Miscellaneous non-inflammatory musculoskeletal conditions. Blau syndrome. Best Pract Res Clin Rheumatol 2011, 25:703-714.
2. Blau E.B. Familial granulomatous arthritis, iritis, and rash. J Pediatr 1985, 107:689-693.
3. Tromp G., Kuivaniemi H., Raphael S., Ala-Kokko L., Christiano A., Considine E., et al. Genetic linkage of familial granulomatous inflammatory arthritis, skin rash, and uveitis to chromosome 16. Am J Hum Genet 1996, 59:1097-1107.
4. Miceli-Richard C., Lesage S., Rybojad M., Prieur A.M., Manouvrier-Hanu S., Häfner R., et al. CARD15 mutations in Blau syndrome. Nat Genet 2001, 29:19-20.
5. Cavanaugh J. NOD2: ethnic and geographic differences. World J Gastroenterol 2006 Jun 21, 12:3673-3677.
6. Kanazawa N., Okafuji I., Kambe N., Nishikomori R., Nakata-Hizume M., Nagai S., et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 2005, 105:1195-1197.
7. Rosé C.D., Doyle T.M., McIlvain-Simpson G., Coffman J.E., Rosenbaum J.T., Davey M.P., et al. Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis. J Rheumatol 2005, 32:373-375.
8. Rosé C.D., Martin T.M., Wouters C.H. Blau syndrome revisited. Curr Opin Rheumatol 2011, 23:411-418.
9. Milman N., Ursin K., Rødevand E., Nielsen F.C., Hansen T.V. A novel mutation in the NOD2 gene associated with Blau syndrome: a Norwegian family with four affected members. Scand J Rheumatol 2009, 38:190-197.
10. van Duist M.M., Albrecht M., Podswiadek M., Giachino D., Lengauer T., Punzi L., et al. A new CARD15 mutation in Blau syndrome. Eur J Hum Genet 2005, 13:742-747.
11. Rybicki B.A., Maliarik M.J., Bock C.H., Elston R.C., Baughman R.P., Kimani A.P., et al. The Blau syndrome gene is not a major risk factor for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999 Sep, 16:203-208.
12. Becker M.L., Rose C.D. Blau syndrome and related genetic disorders causing childhood arthritis. Curr Rheumatol Rep 2005, 7:427-433.
13. Rosé C.D., Wouters C.H., Meiorin S., Doyle T.M., Davey M.P., Rosenbaum J.T., et al. Pediatric granulomatous arthritis: an international registry. Arthritis Rheum 2006, 54:3337-3344.
14. Aróstegui J.I., Arnal C., Merino R., Modesto C., Antonia Carballo M., Moreno P., et al. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 2007, 56:3805-3813.
15. Okafuji I., Nishikomori R., Kanazawa N., Kambe N., Fujisawa A., Yamazaki S., et al. Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. Arthritis Rheum 2009, 60:242-250.
16. Wang X., Kuivaniemi H., Bonavita G., Mutkus L., Mau U., Blau E., et al. CARD15 mutations in familial granulomatosis syndromes: a study of the original Blau syndrome kindred and other families with large-vessel arteritis and cranial neuropathy. Arthritis Rheum 2002, 46:3041-3045.
17. Gattorno M., Federici S., Pelagatti M.A., Caorsi R., Brisca G., Malattia C., et al. Diagnosis and management of autoinflammatory diseases in childhood. J Clin Immunol 2008, 28:S73-83.
18. Manouvrier-Hanu S., Puech B., Piette F., Boute-Benejean O., Desbonnet A., Duquesnoy B., et al. Blau syndrome of granulomatous arthritis, iritis, and skin rash: a new family and review of the literature. Am J Med Genet 1998, 76:217-221.
19. Raphael S.A., Blau E.B., Zhang W.H., Hsu S.H. Analysis of a large kindred with Blau syndrome for HLA, autoimmunity, and sarcoidosis. Am J Dis Child 1993, 147:842-848.
20. Masel G., Halbert A. Blau syndrome presenting with ichthyosis. Australas J Dermatol 2005, 46:29-32.
21. Milman N., Andersen C.B., Hansen A., van Overeem Hansen T., Nielsen F.C., Fledelius H., et al. Favourable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation. APMIS 2006, 114:912-919.
22. Alonso D., Elgart G.W., Schachner L.A. Blau syndrome: a new kindred. J Am Acad Dermatol 2003, 49:299-302.
23. Jabs D.A., Houk J.L., Bias W.B., Arnett F.C. Familial granulomatous synovitis, uveitis, and cranial neuropathies. Am J Med 1985, 78:801-804.
24. Hafner R., Vogel P. Sarcoidosis of early onset. A challenge for the pediatric rheumatologist. Clin Exp Rheumatol 1993, 11:685-691.
25. Latkany P.A., Jabs D.A., Smith J.R., Rosenbaum J.T., Tessler H., Schwab I.R., et al. Multifocal choroiditis in patients with familial juvenile systemic granulomatosis. Am J Ophthalmol 2002, 134:897-904.
26. Kurokawa T., Kikuchi T., Ohta K., Imai H., Yoshimura N. Ocular manifestations in Blau syndrome associated with a CARD15/Nod2 mutation. Ophthalmology 2003, 110:2040-2044.
27. Snyers B., Dahan K. Blau syndrome associated with a CARD15/NOD2 mutation. Am J Ophthalmol 2006, 14:1089-1092.
28. Saini S.K., Rose C.D. Liver involvement in familial granulomatous arthritis (Blau syndrome). J Rheumatol 1996, 23:396-399.
29. Ting S.S., Ziegler J., Fischer E. Familial granulomatous arthritis (Blau syndrome) with granulomatous renal lesions. J Pediatr 1998, 133:450-452.
30. Emaminia A., Nabavi M., Mousavi Nasab M., Kashef S. Central nervous system involvement in Blau syndrome: a new feature of the syndrome?. J Rheumatol 2007, 34:2504-2505.
31. Dhondt V., Hofman S., Dahan K., Beele H. Leg ulcers: a new symptom of Blau syndrome?. Eur J Dermatol 2008, 18:635-637.
32. Mourad F., Tang A. Sinus of valsalva aneurysm in Blau's syndrome. J Cardiothorac Surg 2010 Mar 26, 5:16.
33. Akil I., Ozguven A., Canda E., Yilmaz O., Nese N., Ozkol M., et al. Co-existence of chronic renal failure, renal clear cell carcinoma, and Blau syndrome. Pediatr Nephrol 2010, 25:977-981.
34. Becker M.L., Martin T.M., Doyle T.M., Rosé C.D. Interstitial pneumonitis in Blau syndrome with documented mutation in CARD15. Arthritis Rheum 2007, 56:1292-1294.
35. Yasui K., Yashiro M., Tsuge M., Manki A., Takemoto K., Yamamoto M., et al. Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism. Arthritis Rheum 2010, 62:250-257.
36. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cézard J.P., Belaiche J., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
37. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
38. Schaffer J.V., Chandra P., Keegan B.R., Heller P., Shin H.T. Widespread granulomatous dermatitis of infancy: an early sign of Blau syndrome. Arch Dermatol 2007, 143:386-391.
39. Rosé C.D., Aróstegui J.I., Martin T.M., Espada G., Scalzi L., Yagüe J., et al. NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain. Arthritis Rheum 2009, 60:1797-1803.
40. Kanazawa N., Matsushima S., Kambe N., Tachibana T., Nagai S., Miyachi Y. Presence of a sporadic case of systemic granulomatosis syndrome with a CARD15 mutation. J Invest Dermatol 2004, 122:851-852.
41. Ogura Y., Inohara N., Benito A., Chen F.F., Yamaoka S., Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001, 276:4812-4818.
42. Tada H., Aiba S., Shibata K., Ohteki T., Takada H. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect Immun 2005, 73:7967-7976.
43. Ogura Y., Lala S., Xin W., Smith E., Dowds T.A., Chen F.F., et al. Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut 2003, 52:1591-1597.
44. Barnich N., Aguirre J.E., Reinecker H.C., Xavier R., Podolsky D.K. Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor-{kappa}B activation in muramyl dipeptide recognition. J Cell Biol 2005, 170:21-26.
45. Rosenstiel P., Fantini M., Bräutigam K., Kühbacher T., Waetzig G.H., Seegert D., et al. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003, 124:1001-1009.
46. Strober W., Murray P.J., Kitani A., Watanabe T. Signaling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 2006, 6:9-20.
47. Chen G., Shaw M.H., Kim Y.G., Nuñez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 2009, 4:365-398.
48. Zurek B., Proell M., Wagner R.N., Schwarzenbacher R., Kufer T.A. Mutational analysis of human NOD1 and NOD2 NACHT domains reveals different modes of activation. Innate Immun 2012, 18:100-111.
49. Inohara N., Ogura Y., Fontalba A., Gutierrez O., Pons F., Crespo J., et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003, 278:5509-5512.
50. Opitz B., Püschel A., Schmeck B., Hocke A.C., Rosseau S., Hammerschmidt S., et al. Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J Biol Chem 2004, 279:36426-36432.
51. Ferwerda G., Girardin S.E., Kullberg B.J., Le Bourhis L., de Jong D.J., Langenberg D.M., et al. NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog 2005, 1:279-285.
52. Girardin S.E., Boneca I.G., Viala J., Chamaillard M., Labigne A., Thomas G., et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003, 278:8869-8872.
53. Kobayashi K.S., Chamaillard M., Ogura Y., Henegariu O., Inohara N., Nuñez G., et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005, 307:731-734.
54. Divangahi M., Mostowy S., Coulombe F., Kozak R., Guillot L., Veyrier F., et al. NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. J Immunol 2008, 181:7157-7165.
55. Sabbah A., Chang T.H., Harnack R., Frohlich V., Tominaga K., Dube P.H., et al. Activation of innate immune antiviral responses by Nod2. Nat Immunol 2009, 10:1073-1080.
56. Lipinski S., Till A., Sina C., Arlt A., Grasberger H., Schreiber S., et al. DUOX2-derived reactive oxygen species are effectors of NOD2-mediated antibacterial responses. J Cell Sci 2009, 122:3522-3530.
57. Travassos L.H., Carneiro L.A., Ramjeet M., Hussey S., Kim Y.G., Magalhães J.G., et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010, 11:55-62.
58. Barnich N., Hisamatsu T., Aguirre J.E., Xavier R., Reinecker H.C., Podolsky D.K. GRIM-19 interacts with nucleotide oligomerization domain 2 and serves as downstream effector of anti-bacterial function in intestinal epithelial cells. J Biol Chem 2005, 280:19021-19026.
59. Magalhaes J.G., Lee J., Geddes K., Rubino S., Philpott D.J., Girardin S.E. Essential role of Rip2 in the modulation of innate and adaptive immunity triggered by Nod1 and Nod2 ligands. Eur J Immunol 2011, 41:1445-1455.
60. Kobayashi K., Inohara N., Hernandez L.D., Galán J.E., Núñez G., Janeway C.A., et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 2002, 416:194-199.
61. Chamaillard M., Philpott D., Girardin S.E., Zouali H., Lesage S., Chareyre F., et al. Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci U S A 2003, 100:3455-3460.
62. Rodríguez-Pérez N., Aguinaga-Barrilero A., Gorroño-Echebarría M.B., Pérez-Blas M., Martín-Villa J.M. Blau syndrome-related CARD15/NOD2 mutations are not linked to idiopathic uveitis in Spanish patients. Dis Markers 2009, 27:1-5.
63. Albrecht M., Lengauer T., Schreiber S. Disease-associated variants in PYPAF1 and NOD2 result in similar alterations of conserved sequence. Bioinformatics 2003, 19:2171-2175.
64. Pastores G.M., Michels V.V., Stickler G.B., Su W.P., Nelson A.M., Bovenmyer D.A. Autosomal dominant granulomatous arthritis, uveitis, skin rash, and synovial cysts. J Pediatr 1990, 117:403-408.
65. de Chadarévian J.P., Raphael S.A., Murphy G.F. Histologic, ultrastructural, and immunocytochemical features of the granulomas seen in a child with the syndrome of familial granulomatous arthritis, uveitis, and rash. Arch Pathol Lab Med 1993, 117:1050-1052.
66. Moraillon I., Hayem F., Bourrillon A., Morel P., Rybojad M. Blau syndrome or familial form of sarcoidosis with onset during infancy. Ann Dermatol Venereol 1996, 123:29-30.
67. Scerri L., Cook L.J., Jenkins E.A., Thomas A.L. Familial juvenile systemic granulomatosis (Blau's syndrome). Clin Exp Dermatol 1996, 21:445-448.
68. Ewida A.S., Raphael S.A., Abbasi J.A., Geslani G.P., Bagasra O. Evaluation of Th-1 and Th-2 immune responses in the skin lesions of patients with Blau syndrome. Appl. Immunohistochem. Mol. Morphol. 2002, 10:171-177.
69. Villanueva-Mendoza C., Arellanes-García L., Cubas-Lorenzo V., Jimenez-Martinez M.C., Flores-Suárez L.F., Zenteno J.C. Familial case of Blau syndrome associated with a CARD15/NOD2 mutation. Ophthalmic Genet 2010, 31:155-158.
70. Stoevesandt J., Morbach H., Martin T.M., Zierhut M., Girschick H., Hamm H. Sporadic Blau syndrome with onset of widespread granulomatous dermatitis in the newborn period. Pediatr Dermatol 2010, 27:69-73.
71. Son S., Lee J., Woo C.W., Kim I., Kye Y., Lee K., et al. Altered cytokine profiles of mononuclear cells after stimulation in a patient with Blau syndrome. Rheumatol Int 2010, 30:1121-1124.
72. Martin J., Kodjikian L., Duquesne A., Le Scanff J., Sève P. Blau syndrome. QJM 2011, 104:997-998.
73. Raiji V.R., Miller M.M., Jung L.K. Uveitis in Blau syndrome from a de novo mutation of the NOD2/CARD15 gene. J AAPOS 2011, 15:205-207.
74. Jimenez-Martinez M.C., Cruz F., Groman-Lupa S., Zenteno J.C. Immunophenotyping in peripheral blood mononuclear cells, aqueous humour and vitreous in a Blau syndrome patient caused by a novel NOD2 mutation. Int J Immunogenet 2011, 38:233-242.
75. Xiang H., Zhang T., Chen M., Zhou X., Li Z., Yan N., et al. NOD2/CARD15 gene mutation identified in a Chinese family with Blau syndrome. Mol Vis 2012, 18:617-623.
76. Saulsbury F.T., Wouters C.H., Martin T.M., Austin C.R., Doyle T.M., Goodwin K.A., et al. Incomplete penetrance of the NOD2 E383K substitution among members of a pediatric granulomatous arthritis pedigree. Arthritis Rheum 2009, 60:1804-1806.
77. Sakai H., Ito S., Nishikomori R., Takaoka Y., Kawai T., Saito M., et al. A case of early-onset sarcoidosis with a six-base deletion in the NOD2 gene. Rheumatology (Oxford) 2010, 49:194-196.